Value of 4CMenB infant vaccination in England re-examined
- PDF / 167,316 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 86 Downloads / 175 Views
1
Value of 4CMenB infant vaccination in England re-examined Infant vaccination with the 4-component meningococcal B vaccine 4CMenB [Bexsero] can be cost effective in England when considering the broad burden of serogroup B invasive meningococcal disease (MenB IMD) comprehensively. This is the main finding of a study that used a dynamic transmission-based cost-effectiveness model to provide a comprehensive cost-effectiveness analysis (CEA) of 4CMenB infant vaccination in England that included the broadranging disease burden of MenB IMD.* Five disease-burden categories were identified taking account of the long-term impact of MenB IMD on the patient, family, network, caregivers and society. The 4CMenB infant national immunisation programme (NIP) was predicted to rapidly reduce the incidence of MenB IMD within 5 years of vaccine introduction in 2015, in particular in infants and young children (by 64% in infants and children aged 4–23 months and by 46.0% in children aged 0–4 years). In the baseline scenario, without taking account of disease burden more comprehensively, the incremental cost-effectiveness ratio (ICER) for 4CMenB infant vaccination was estimated at £360 595/QALY in a previous CEA. Inclusion of the impact of long-term sequelae on patients reduced the ICER to £170 409/QALY, and stepwise inclusion of the other disease-burden categories reduced the ICER to £18 645/QALY. At a cost-effectiveness threshold of £20 000/QALY gained and with a UK list price of £75 per dose, the 4CMenB infant programme is cost effective when considering the broad disease burden, conclude the researchers. * The study was funded by GlaxoSmithKline Biologicals SA. Beck E, et al. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. Value in Health : 28 Oct 2020. Available from: URL: https://doi.org/10.1016/j.jval.2020.09.004
1173-5503/20/0866-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803513919
PharmacoEconomics & Outcomes News 14 Nov 2020 No. 866
Data Loading...
